The role of inhibins and activins in prostate cancer pathogenesis

C R Dowling and G P Risbridger

Institute of Reproduction and Development, Monash University, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria 3168, Australia

Abstract

Successful prostate cancer diagnosis and management continue to provide challenges for the clinician. While interventions aimed at the containment of both early and late disease continue to fail in a significant number of patients, the search for answers must incorporate an analysis of the processes of normal and aberrant growth and development within the gland itself. Inhibin and its structurally related protein, activin, are members of the transforming-growth-factor $\beta$ (TGF$\beta$) superfamily. Originally identified as regulators of FSH, these proteins are now recognised to have widespread biological functions. This might be expected of proteins that are structurally homologous to TGF$\beta$ itself, which is recognised to have regulatory roles in both normal and malignant prostate tissue. The aim of this review is to examine the relationship between inhibins, activins and their related proteins and the development of prostate cancer. The homology with TGF, the pluripotent effects of activin on various tissues and the roles for inhibins in ovarian cancer make activins and inhibins candidate growth factors for involvement at multiple sites in the progression from benign disease to cancer. In compiling this review, we aim to delineate the changes in inhibins and activins in this pathway and in doing so implicate their potential roles in the progression of carcinogenesis. We will compare the changes in inhibin and its related proteins in prostate cancer to those that are known in ovarian cancer. We will discuss the similarities and differences between the putative role of activins and TGF$\beta$ in prostate carcinogenesis. The importance of this review lies in demonstrating that inhibin, an endocrine hormone, and its related proteins may contribute to endocrine-related cancers, such as that of the prostate gland.

Introduction

Prostate cancer is the most frequently diagnosed cancer in men in the developed world, excluding skin cancers, and is the second commonest cause of cancer-related death in men after lung cancer. Despite these important statistics, it is a misguided perception that prostate cancer does not represent as great a health problem for the male population as breast cancer does for the female population. This may be because prostate cancer affects men about a decade later in life than breast cancer affects women. In the USA the average age at diagnosis for carcinoma of the prostate is 71 years and for breast carcinoma 64 years (SEER 1973–1991). Whilst there are a few cases of prostate cancer in older men that may not significantly shorten their life, men who are diagnosed with the disease in their sixties have an 80% chance of dying as a direct result of their cancer (Aus & Hugosson 1997, Johansson et al. 1997).

Efforts to significantly halt the progress of prostate cancer have been frustrated by lack of a highly sensitive and specific screening tool to detect cancer at a stage at which it is confined within the gland, and by the lack of an effective treatment with minimal morbidity. For the urologist, significant progress in patient management would be possible if a method existed to allow prediction of those cases that might progress from apparently organ-confined disease, and therefore require active management. Additionally, identifying those cases in which it may be appropriate for conservative management is a significant clinical challenge. The importance of determining the role of endocrine and paracrine control mechanisms in normal development and carcinogenesis in the prostate cannot be overstated. Their identification is likely to prove crucial in any future ability to target the disease earlier, to initiate new therapies, to select cases that are more likely to be aggressive, and to control the disease once it reaches androgen independence.
Pathways of prostate carcinogenesis, roles for growth factors and justification for the study of inhibin and activin in cancer

In 1941, Huggins & Hodges discovered that prostate development and disease was driven by androgens. Whilst a direct role for androgens in the stimulation of cancer growth is recognised, their indirect actions via growth factors and cytokines, including transforming-growth factor β (TGFβ) and fibroblast growth factor, is an emerging field. It is also conceivable that growth factors will have roles that are both androgen dependent and androgen independent, possibly providing potential sites of intervention in androgen-independent disease, which is currently refractory to treatment. Therefore, there is motivation for the search for these different regulatory proteins, including members of the TGFβ superfamily, which is widely recognised to have a role in carcinogenesis. Many growth factors, including TGFβ, are implicated in the pathogenesis of other cancers (Blobe et al. 2000). The receptors for TGFβ ligands and the signalling proteins comprise a tumour-suppressor pathway in carcinogenesis (Fig. 1) and development of resistance to TGFβ by tumour cells represents a key event in the progression of malignancy (Kim et al. 2000).

While the specific involvement of TGFβ in the pathogenesis of cancer is accepted, the case for inhibin and activin is less distinct. Inhibin and activin have normal biological roles distinct from those of TGFβ. Inhibin is involved in reproductive regulation and activin has reproductive roles and also regulates crucial phases of development, such as mesoderm induction and dorsoventral patterning. Inhibins and activins are also important in branching morphogenesis and the reader is referred to a review of this work (Risbridger & Cancilla 2000). There is potential, however, for inhibin and activin to function in other biological systems in a manner similar to TGFβ, and indeed redundancy may exist. Activins and inhibins have been identified in tumours as diverse as prostate, ovarian, pancreatic, pituitary, breast and the gastrointestinal tract. It is possible, then, that the roles of activins and inhibins may prove to be of similar importance to TGFβ during carcinogenesis, particularly in the case of activin. While inhibin may have roles in the pathogenesis of other endocrine-related cancers, in particular breast cancer, currently little is known about breast cancer in the context of inhibins and activins (Di Loreto et al. 1999, McCluggage & Maxwell 1999).

Inhibin is known to be a serum marker in some subtypes of ovarian cancer and levels of immunoreactive inhibin are elevated in almost all patients with granulosa cell tumours and the majority of postmenopausal women with mucinous ovarian carcinoma (Burger et al. 1998). While the elevation of serum inhibin α subunits is associated with the development of ovarian cancer, the cellular pathways to tumour development in ovarian carcinoma that involve inhibin and its related proteins are not fully understood.

Further evidence for the potential importance of TGFβ superfamily proteins in carcinogenesis is supported by the role of bone morphogenetic proteins (BMPs). These members of the TGFβ superfamily both have roles in the regulation of bone remodelling and are expressed in a variety of non-skeletal sites, consistent with possible wider roles in diverse tissues (Paralkar et al. 1998). Inhibins and the related proteins, activins, are members of the TGFβ growth factor superfamily and demonstrate 30% structural homology with TGFβ (Mason et al. 1986). Whilst inhibin is recognised to function as an endocrine hormone (de Kretser & McFarlane 1996), the related activin dimers have important roles in growth, differentiation and development. As we shall discuss, many of these roles comprise important steps in cancer progression, including effects on wound healing and tissue repair, immune function and regulation of the cardiovascular system. These characteristics make it reasonable to suggest that activin may have an important role in the development and progression of cancer.

Defining prostatic inhibin

The existence of additional proteins such as inhibin with capabilities of regulating follicle-stimulating hormone (FSH) was predicted as long as 60 years ago. McCullagh’s demonstration of the suppression of anterior pituitary or ‘castration’ cells by bovine testicular fluid raised the idea that the FSH system was subject to endocrine influences beyond those that were already recognised (McCullagh 1932).

In the 1980s seminal plasma was used as a source of material for purification programmes and inhibin activity was identified in this biological fluid (Beksac et al. 1984). When the inhibin genes were isolated and cloned in the1980s it was revealed that the inhibin protein in seminal plasma was not related to dimeric inhibin (Robertson et al. 1985, Mason et al. 1986). In fact, seminal plasma inhibin is a major secretory product of the prostate and represents about 20% of total secreted protein in seminal plasma. It is distinct from dimeric inhibin, because it is a single chain polypeptide of 94 amino acids. In reviewing the body of literature referring to inhibin it is important to clarify this point, in order to avoid any further confusion. Different authors have reported seminal plasma inhibin as inhibin or prostatic inhibin peptide, β-microsemionoprotein, immunoglobulin-binding factor and prostatic secretory protein of 94 amino acids. Over almost two decades evidence has accumulated to show that this protein is a major secretory product of the prostatic epithelium and that it may be altered in benign and malignant tissues and cell lines (Teni et al. 1988). There is some evidence that it may be a useful biomarker of...
Figure 1 Summary of some of the similarities and differences between activin and TGFβ ligands. Activin’s receptor binding and local and distant effects are shown on the left-hand side of the figure. Those of TGFβ are on the right-hand side. The two ligands have similar receptor activation mechanisms, through classes of receptors that contain a serine/threonine kinase domain. Intracellularly, the Smad proteins are involved in both systems. Before receptor binding, TGFβ is activated from a latent form. Activin is active but may be modified either by follistatin binding or through dominant negative receptor binding by inhibin and betaglycan. Activin RII receptor component mutations, similar to that known to involve components of the TGFβ receptor, have been suggested to occur. Alterations in Smad proteins are also implicated in the pathway to carcinogenesis. The ‘responses’ to activin and TGFβ are ‘local’ or ‘distant’ as indicated. Local responses are shown as their effects on normal cells, LNCaP and PC3 prostate cancer cell lines. The distant effects are similar for wound healing and immunosuppression. Activin has a more defined role in bone remodelling and TGFβ is known to have angiogenic properties.
prostate cancer, but the review of that literature is outside the scope of this article (Garde et al. 1994).

The inhibin and activin ligands

Mature inhibin is a 31 to 32 kDa heterodimeric glycoprotein. Two forms exist, both containing the common β subunit (18 kDa) joined to a subunit (14 kDa) by disulphide bridges. The two most commonly recognised β subunits are βA and βB. Dimerisation with the α subunit leads to the formation of inhibin A (αβA) and inhibin B (αβB) (Burger 1988, Ying 1988). Activin proteins are formed by the dimerisation of the β subunits, βA and βB. Specific roles of the various subunits are incompletely defined but differential expression of the subunits in tissues may lead to preferential formation of particular activin proteins. Dimerisation results in three protein combinations, namely activin A (βAβA), activin B (βBβB) and activin AB (βAβB). Where it has been possible to measure the level of the individual ligands in differing biological situations, such as the menstrual cycle and pregnancy, changes have been demonstrated (McLachlan et al. 1987).

Additional β subunits, βC, βB and βE, have been characterised. The βC and βB subunits have been cloned from mouse (Fang et al. 1996, Lau et al. 1996). The βE subunit has been cloned from Xenopus but no mammalian equivalent has yet been described (Oda et al. 1995). We have recently reported that βC dimerises, forming activin C. However, studies have failed to demonstrate dimerisation of βE with the subunit and hence formation of a putative inhibin C (αβE) (Mellor et al. 2000). It is not yet known if the formation of other dimers involving βC, βB and βE occurs.

Inhibin and activin receptors and signalling

Knowledge of the TGFβ receptor, which contains serine/threonine kinase domains, has helped to characterise the initial steps in the mechanism of activin interaction with its receptor. Delineation of an intracellular signalling pathway for inhibin awaits unequivocal proof of a receptor for inhibin, about which controversy regarding its very existence persists. The evidence presented supporting the existence of an inhibin receptor is based on the identification of specific binding sites for inhibin on ovarian granulosa cells and Leydig cells (Woodruff et al. 1990, 1993, Krummen et al. 1994). Additional supporting data for the existence of a specific receptor include the demonstration of an inhibin-specific protein complex, k562, in haematopoietic cell lines (Lebrun & Vale 1997) and tumour-derived inhibin receptor proteins in the Matzuk inhibin knockout mice (Draper et al. 1998).

In contrast to these findings, it is suggested that inhibin does not act through a receptor, but exerts its effect through a dominant negative mechanism. This hypothesis was initially put forward after the report that inhibin A had no activity of its own in liver cell growth and that it served principally to inhibit the anti-proliferative action of activin A on HepG2 cells (Xu et al. 1995). Xu and colleagues proposed that inhibin antagonised the effect of activins by blocking activin-receptor binding. This mechanism was recently re-evaluated, as a result of the report that the type III TGFβ receptor, betaglycan, can function as a co-receptor with specific activin type II (ActRII or ActRIIB) receptor serine kinases (Lewis et al. 2000). Specifically, it was proposed that betaglycan facilitated the antagonism of activin action by inhibin. Some support for this hypothesis was drawn by analogy with the mechanism of control of the melanocyte-stimulating hormone (MSH) ligand. For MSH action, the proteoglycan, mahogany, acts as the betaglycan does for inhibin, by facilitating binding of the MSH antagonist, agouti, to the MSH receptor. Hence it was proposed that inhibin and betaglycan bind and block ligand (activin) access to the receptor, just as the binding of agouti to mahogany blocks the access of MSH to its receptor, resulting in a dominant negative disruption of the MSH signal (Gunn et al. 1999, Nagle et al. 1999).

The activin receptor is typical of the TGFβ superfamily, being comprised of two structurally related classes of receptors (type I and type II), both containing a serine/threonine kinase domain (Mathews & Vale 1991). The type I and type II components are composed of single membrane spanning subunits designated type RI (50–55 kDa) and type RII (70–75 kDa) (Mathews 1994). The receptor mediates ligand action after the RII component trans-phosphorylates the RI domain (Fig. 1). Phosphorylation of RII is not necessary for downstream signalling but RII must bind RI in order for signalling to occur. RII can bind activin alone. Mutations of both the RI and RII components have been described but mutations of single residues in RI fail to inhibit activity. Analogous conclusions can be drawn from mutational analysis of TGFβ receptor subunits (Woodruff 1998). It is recognised that prostate cancer cells may reduce the expression of TGFβ receptor subunits (TβRI-1 or TβRII-1) in order to escape the growth-inhibitory effects of TGFβ (Lee et al. 1999). Whilst this binary receptor is similar for all ligands of the TGFβ superfamily, discrimination between the different ligands is high and is determined by differential binding to the RII component (Woodruff 1998). For activin, there are two known ligand-binding type II receptor genes, type II and type IIB.

A common model for intracellular signalling involving activin and other TGFβ superfamily proteins is via intracellular heterodimeric and homodimeric Smad (Sma genes and mothers against dpp (Mado)) proteins (Fig. 1). Smads are the direct cytoplasmic substrates for the TGFβ superfamily. Smad2 is involved in the pathway for both TGFβ and activin signalling (Lagna et al. 1996, Wu et al.
interaction of follistatins with activins is its most commonly
activin via the
β
FS315 to stromal cells (Thomas
differ, with FS288 isolated principally to basal cells and
acids respectively). In the prostate, their cellular distributions
mRNAs (FS288 and FS315, containing 288 and 315 amino
95% structural homology in mammals (Phillips & de Kretser
amino acid difference between rat and human protein and
of follistatin is highly conserved between species, with a two
attenuate the response of TGF
β
Mutations of the DNA binding sites have been shown to
therefore conceivable they have a role in tumour formation.
In addition to mediating their actions via receptor signalling,
activin and inhibin are known to associate with binding
proteins such as α2-macroglobulin (Vaughan & Vale 1993).
However, the most well known and functionally important
interaction is between activins and follistatins. Follistatins are
structurally distinct from inhibin and activin. Follistatins are
glycosylated proteins now recognised to be members of a
larger group of proteins with a well-conserved secondary
structure that has a ‘follistatin’ domain that is rich in
cysteine. Other proteins that are members of this group include
agrin, secreted protein rich in cysteine (SPARC, also
known as BM40 and osteonectin), testican, hevin and
follistatin-related protein (Phillips & de Kretser 1998).
Nine molecular weight forms of follistatin are postulated, based
on a core protein with a varying degree of glycosylation, and
six have been identified (Sugino et al. 1993). The structure of
follistatin is highly conserved between species, with a two
amino acid difference between rat and human protein and
95% structural homology in mammals (Phillips & de Kretser
1998). Follistatins arise from two alternatively spliced
mRNAs (FS288 and FS315, containing 288 and 315 amino
acids respectively). In the prostate, their cellular distributions
differ, with FS288 isolated principally to basal cells and
FS315 to stromal cells (Thomas et al. 1998).
Follistatins exhibit an inhibin-like suppression of FSH
(Robertson et al. 1987) and have affinity for inhibin and
activin via the β subunit (Shimonaka et al. 1991). The interaction of follistatins with activins is its most commonly
recognised biological action, but a possible individual role in
angiogenesis has also been suggested (Kozian et al. 1997).
Follistatin also exerts biological effects through the binding
of other TGFβ superfamily proteins, the BMPs (Yamashita

Inhibin, activin and prostate cancer

Inhibins and prostate cancer

The majority of current knowledge of the activins and
inhibins in human cancer relates to ovarian and prostate
cancer. The focus in ovarian cancer has been on the role of
the inhibin subunit (Lappohn et al. 1989). There is also an
important role for inhibin and, in particular, its subunit in
prostate cancer. Expression and localisation of inhibin and
activin subunits in normal and benign prostate tissue have
been defined using both immunohistochemistry and isolation
of mRNA (Thomas et al. 1997). Based upon these findings,
it is known that the normal distribution of proteins is altered
in prostate disease and carcinogenesis.

Studies from this laboratory have shown that the human
prostate synthesises dimeric inhibins and activins, including
the inhibin subunit and A, B and C (Thomas et al. 1998). In
non-malignant tissue or benign prostatic hyperplasia (BPH),
subunit mRNA was expressed, but detection of protein was
more problematic because of antibody specificity. A
commonly used Groome antibody did not demonstrate
immunoreactivity; however, there was immunoreactivity to
others, such as those raised to the carboxyl- and
amino-terminal (αc and αs) regions of the α subunit terminal
region (Mellor et al. 1998). Both inhibin A and B are
secreted to seminal fluid (Anderson et al. 1998) but the
relative ratios and function of the ligands are unknown and
it is not known whether inhibin A or B represents the
predominant form in the prostate.

Loss of inhibin subunit expression

Loss of expression of inhibin subunits in high-grade prostate
cancer has been demonstrated by in situ hybridisation and
immunoreactivity to antibodies that are able to determine the
expression of subunits in normal prostate (see Fig. 2) (Mellor
et al. 1998). Down-regulation of gene expression and the
absence of mRNA or protein in tissues from high-grade
disease was observed (Mellor et al. 1998). These data and
the findings of gonadal tumour development in the Matzuk
knockout mice (Matzuk et al. 1992) support the hypothesis that the inhibin α subunit has a role as a tumour suppressor
in prostate cancer. Matzuk and colleagues first suggested a
role for the inhibin subunits in carcinogenesis. Specifically,
they proposed that the inhibin α subunit might act as a
tumour suppressor because subunit knockout mice developed
mixed or incompletely differentiated gonadal stromal
tumours and, when castrated, adrenal tumours were noted to
arise (Matzuk et al. 1992).
Figure 2 This demonstrates the loss of α subunit expression in high-grade prostate carcinoma. Localisation of αC and αN inhibin protein and inhibin α subunit mRNA to non-malignant and malignant regions of prostate tissues from patients with high-grade prostate cancer. αC inhibin was localised to the basal epithelial cells in the non-malignant region (A) of the prostate biopsy. The adjacent tumour cells displayed no immunoreactivity (B). Specific localisation of αN protein was observed in the secretory epithelium of the non-malignant region (C); the adjacent tumour tissue displayed no staining (D). A control section was incubated with sheep IgG and displayed no specific immunoreactivity (E and F). α inhibin mRNA was expressed in basal epithelial cells in the non-malignant region (G). The adjacent malignant region showed no immunolocalisation (H). The control section incubated with the sense probe displayed no signal (I and J). Scale bar = 100µm. (Reproduced with permission from Mellor et al. (1998) Journal of Clinical Endocrinology and Metabolism 83 973; Fig. 3.)
The characteristics of the prostates in Matzuk inhibin-deficient mice were not described. However, the primary sex cord stromal tumours lead to death in more than 95% of the male mice at 12 weeks. This is likely to be too early to see hyperplastic or neoplastic changes in the mouse prostate. The genetically manipulated mouse had not been a particularly useful way to study human prostate cancer because, in order to induce prostate cancer, most groups use Simian virus 40 T-antigens plus or minus prostate specific promoters; these viral oncoproteins are not etiologic agents for prostate cancer and have multiple cellular actions. Furthermore, the mouse prostate has marked anatomical differences from the human prostate and therefore may not represent the ideal animal for the development of a model for human prostate cancer (Sharma & Schreiber-Agus 1999).

In human cancers, the down-regulation of tumour suppressor genes may be associated with a loss of heterozygosity or promoter hypermethylation. Unpublished data from this laboratory show that both mechanisms occur in prostate cancer (JF Schmitt & GP Risbridger). The inhibin gene was localised to the 2q33 chromosomal locus in the human genome and deletions on chromosome 2q occur in gene was localised to the 2q33 chromosomal locus in the human genome and deletions on chromosome 2q occur in human tumours, including ovarian, bladder and hepatocellular carcinomas (Nagai et al. 1997, Saretzki et al. 1997, Watson et al. 1997). Frequent loss of chromosome 2 occurs and this region was identified as a candidate region in hereditary forms of prostate cancer (Alers et al. 2000, Suarez et al. 2000) although deletions for 2q33 have not been specifically reported.

In vitro data also support the loss of the α subunit. In cultured prostate cancer cell lines, there is no detectable inhibin α gene or protein expression in LNCaP (androgen sensitive), DU145 (relatively androgen sensitive) and PC3 (androgen insensitive) lines (Thomas et al. 1997).

In vitro studies and dominant negative receptor function

The effect of exogenous inhibin on prostate cancer cell lines is conflicting. We have shown that there was no effect on cell growth with application of inhibin A to LNCaP, DU145 or PC3 prostate cancer cell lines (McPherson et al. 1997). While a small degree of decreased proliferation of the LNCaP cell line has been demonstrated with the addition of inhibin, this was at one-hundredth of the potency demonstrated with activin (Wang et al. 1996). Explanations offered for this minimal growth-inhibitory response include inhibin acting in either a dominant negative mechanism with the activin receptor, with greater affinity for the type IIIB than type II component, or direct binding by inhibin of its own receptor. The dominant negative theory is supported by the mechanism already discussed, where inhibin can bind the type II moiety of the activin receptor, resulting in failure to then recruit the type I receptor to complete the complex (Draper et al. 1998). However, Wang et al. (1996) favour the concept of binding to an inhibin receptor, as the inhibin effect was additive to that demonstrated by activin and greater than predicted due to the interruption of activin receptor binding alone.

Activins and prostate cancer

There is little known about the role of activin in normal and non-malignant prostate tissue beyond the finding of expression of β₅, β₆ and β₈ subunits in the epithelium of non-malignant prostate disease and immunohistochemical demonstration of activin A expression by the epithelium of BPH (Thomas et al. 1997). In prostate cancer, in vitro studies have demonstrated the presence of β₅, β₆, and β₈ subunits in all grades of cancer in the epithelial cells. The presence of β₅, β₆, and β₈ expressed in high-grade cancers, in the absence of inhibin α subunit expression, suggests that cells continue to synthesise activins.

So, what then is the role of activins in prostate cancer pathogenesis? The majority of current knowledge in answer to this question is obtained from in vitro studies on prostate cancer cell cultures and these lines do not exhibit a uniform response to activin A.

In vitro studies — an inconsistent response

The local effects of activin A are demonstrated by studies on prostate cancer cell lines, LNCaP (androgen sensitive), DU145 (relatively androgen dependent) and PC3 (androgen independent). A strong growth-inhibitory effect in response to activin A in the prostate cancer cell lines is only seen after addition of exogenous activin A to the LNCaP cell line (Dalkin et al. 1996, Wang et al. 1996, McPherson et al. 1997). This growth inhibition of cell proliferation and induction of apoptosis is dose dependent, and importantly is androgen independent (McPherson et al. 1997). Studies on the DU145 cell line demonstrated only an intermediate growth-inhibitory response to activin A and B with DU145 cells less affected than LNCaP at the same dose. Similar studies on the LNCaP line show an increased expression of prostate specific antigen, prostatic acid phosphatase and the androgen receptor itself occurred in the presence of exogenous activin (Zhang et al. 1997). These activities of activin on cell lines are subtype specific for the proteins as incubation with activin B demonstrated a lesser degree of inhibition than with activin A (Wang et al. 1996).

While activin was found to inhibit proliferation of the LNCaP and to a lesser extent the DU145 prostate cancer cell lines, no growth inhibition was seen in the PC3 cells (McPherson et al. 1997) and we conclude that PC3 cells are insensitive to activin A.

All three cell lines (LNCaP, DU145 and PC3) demonstrate production of β₅, β₆ and β₈ subunit mRNA (McPherson et al. 1997). The use of specific enzyme-linked immunosorbent assays (ELISAs) for activin A have
Activins and follistatins in prostate cancer

The studies on the effects of activin on cell lines and the knowledge of similarities between activin and TGFβ have led to hypotheses to explain the mechanism by which prostate cancer cells overcome the growth-inhibitory effects of activin. PC3 tumour cells may acquire resistance to activin by functional alterations in the activin receptor, in a similar way to that by which tumour cells acquire resistance to TGFβ via its receptors. For example, production of an activin-blocking substance or abnormal post-receptor signalling has been proposed (Fig. 1) (Dalkin et al. 1996). Decreased expression of activin receptor mRNA levels for the ActRIB (type I) receptor component in malignant prostate tissue also supports the possibility that the acquisition of activin resistance in the PC3 cells is due to a receptor-related decrease in the local inhibitory effect of activin (van Schaik et al. 2000). However, receptor-related mechanisms have not been proven to be the exclusive cause of activin resistance demonstrated by PC3 cells.

Paracrine stromal—epithelial interactions are recognised regulatory mechanisms that exist in the prostate as recently reviewed (Grossfeld et al. 1998). In BPH, a normal stromal—epithelial relationship exists between the expression of activin and follistatin. Follistatin (FS315) immunoreactivity is expressed in the stroma and activin A predominantly in the epithelium (Thomas et al. 1999b). More specifically, the follistatin was localised to the fibroblastic but not the smooth muscle stromal elements. In contrast, non-malignant tissue from specimens that also contain prostate cancer show co-localisation of the activin and FS288 but not the smooth muscle stromal elements. In addition, activin receptor type IB (ActRIB) mRNA levels were lower in the PC3 tumour cells than in normal prostate tissue (McPherson et al. 1999). This localization supports the theory that follistatin neutralises the action of activin (see Fig. 3) and is supported by the finding that PC3 tumour cells produce measurable levels of FS288 and activin A protein in both cell lysates and the medium from cultured PC3 cells (McPherson et al. 1999). Both immunohistochemistry and Western blotting of prostate tumour cell lines have demonstrated the presence of follistatins. The distribution of the splice variants differs, with FS315 isolated in all lines, but FS288 was most prominent in the PC3 cells (McPherson et al. 1997). While the relative levels of the follistatins produced by the different cell lines remains to be shown, it is known that FS288 is secreted in large amounts by the PC3 cells but not LNCaP cells (Wang et al. 1996).

The significance of these findings may lie in the observation that FS288 has a greater neutralising effect on activin than FS315 (Sugino et al. 1993). The inhibitory effect of activin A can be blocked in both LNCaP and DU145 cells by the addition of a tenfold excess of FS288 protein. LNCaP cells demonstrate growth inhibition in response to exogenous activin A, which is reversible by the addition of follistatin (McPherson et al. 1997). In the PC3 cells it is currently
suspected that activin’s growth-inhibitory action is neutralised by follistatin production. This would be in the setting of autocrine regulation, favouring tumour growth. It would be interesting to speculate if stripping the prostate cancer cells (PC3) of their follistatin would result in growth inhibition in response to local activin production, in a similar way to that which has been demonstrated in ovarian cancer cell lines (Di Simone et al., 1996, Delbaere et al., 1999). This response has been tested in a different way by treating the PC3 cell with a neutralising follistatin antibody to endogenous FS288. The addition of activin A and the antibody to FS288 in increasing concentrations resulted in a dose-dependent decrease in cell proliferation to approximately 60% of control values. This lends further support to the idea that FS288 production by PC3 cells renders them resistant to the growth-inhibitory effects of activin (McPherson et al., 1999).

A crucial future step in the further analysis of the activin/follistatin interaction is examination of the effects in cell lines cultured from primary tumours as opposed to those from metastases from which LNCaP, DU145 and PC3 are all derived. Preliminary studies on explant primary cells and subcultured epithelial components have confirmed that the cells secreted activin and follistatin in a way similar to that which occurs in the cell lines above (Wang et al., 1999). Exogenous activin addition caused inhibition of proliferation in all cell lines cultured from primary tumours and this was neutralised by the addition of human recombinant follistatin (FS288). The Gleason grading of the 13 unselected carcinoma specimens was not specified and therefore the relative changes with tumour grade remain to be shown (Wang et al., 1999).

The role for follistatin as an individual regulatory protein in the pathogenesis of prostate cancer is unknown. The change in follistatin localisation described with regard to the high-grade prostate cancer cell lines is the most striking, but

Figure 3 This figure demonstrates the measurement of activin A and FS288 production by PC3 prostate tumour cell lines in order to show the effect of follistatin in blocking the inhibitory response exhibited by activin on other cell lines, such as LNCaP. Cell lysates and conditioned media were collected daily from LNCaP and PC3 cells in culture and activin A and FS288 levels were measured by specific ELISA testing. (A) Change in PC3 cell number over the course of the 10–day culture period. Values represent means±S.D. of five replicate wells. (B) Daily cellular content of activin A and FS288 (shown as ng protein/10⁶ cells per day) in PC3 cell lysates collected at 24-h intervals over 10 days in culture. Values represent means±S.D. of five replicate wells. (C) The daily activin A and FS288 levels measured in cell-conditioned media collected at 24-h intervals over 10 days in culture (ng protein/10⁶ cells).*P<0.05 compared with activin A or FS288 levels on day 1. Values represent means±S.D. of four replicate wells. (D) The sum cumulative levels of activin A and FS288 produced by PC3 cells over the course of the culture (ng protein/10⁶ cells). All figures are representative of three separate experiments. (Reproduced with permission from McPherson et al. (1999) Endocrinology 140 5305; Fig. 1.)
this is thought to relate to co-localisation with activin and hence forms part of the overall activin/follistatin interaction. There are individual roles for the splice variants, with FS288 more dominantly expressed in the PC3 cells and having a greater affinity overall for activin. If a shift in expression of FS288 can be demonstrated between grades in primary cancers as opposed to cell lines, this may further delineate the role of this splice variant.

**Alternative mechanisms of resistance to activin action in prostate cancer cell lines**

Follistatin binding, with or without activin receptor mutations (Fig. 1), does not currently offer the complete explanation for the development of activin resistance in PC3 prostate cancer cell lines. The formation of novel activin dimers, such as activin C, with different functional characteristics, is another mechanism by which the action of activin may be mitigated. While βC subunit mRNA was identified in earlier work (Thomas et al. 1998b, it has only recently been cloned from DU145 tumour cells (Mellor et al. 2000). The cloned βC is identical to that cloned from human liver, except for a substitution at amino acid 19 (in the signalling sequence) where cytosine was replaced by thymine. Co-transfection into human kidney 293 cells and the development of a monoclonal antibody to βC has enabled the identification of novel activin dimers, including activin C, activin AC and activin BC. Immunoreactivity for βA, βB and βC subunits is found in prostate cancer and there is co-localisation of the βA and βC subunit proteins as well as the B and C subunit proteins to basal cells. Activin C dimeric protein does not alter DNA synthesis of LNCaP cells (Mellor et al. 2000). However, it could be speculated that, through the heterodimerisation of βA with βC, the levels of biologically active activin A may decline, inhibiting the antiproliferative effect of activin A on prostate tumour cells.

**Activins and TGFβ**

TGFβ has a recognised role in the regulation of prostate growth in normal homeostasis and disease states (Dalkin et al. 1996, Barrack 1999, Lee et al. 1999). In prostate cancer, TGFβ mRNA and binding sites are up-regulated after androgen withdrawal and before apoptosis occurs. TGFβ is known to inhibit the growth of DU145 and PC3 cell lines but also has proliferative as well as antiproliferative actions, as it increases the biological aggressiveness of Dunning rat prostate cancer cell lines (Steiner & Barrack 1992). TGFβ actions are clearly complex and may depend on the interplay of multiple other processes, including the hormonal environment and receptor function. In comparison, activin has an effect in cell lines different from TGFβ, as TGFβ causes rapid inhibition of the PC3 cells but not the LNCaP cells (Piek et al. 1997). The explanation offered for this difference is reduced expression of the TGFβ type I receptor in the LNCaP line. It is likely that both activin and TGFβ have some similar and additional different receptor resistance mechanisms. Unlike activin, TGFβ is secreted in a latent form and activational changes may dictate its biological responses.

In summary, the breadth of knowledge on the roles of activin and inhibin in prostate cancer is expanding. The key messages currently, regarding the involvement of inhibins and activins in prostate cancer, concern the possibility that the inhibin subunit acts as a tumour suppressor and that local resistance to activin is possible through its interaction with follistatin. In addition, activin has the capacity to mediate changes distantly that favour tumour progression. Some of activin’s actions locally and distantly may prove to be similar to those of TGFβ, but at present their effects on prostate cancer cell lines are recognisably different (Fig. 1).

**Conclusions**

Inhibin may act as a tumour suppressor in prostate cancer. It is relevant then to briefly revisit the role of inhibin in ovarian carcinoma where it is now recognised there are changes in expression of the various inhibin and activin subunits. While carcinoma of the prostate is histologically an adenocarcinoma in 95% of cases, there are several histological variants of ovarian carcinoma, broadly the surface epithelial—stromal tumours, the sex cord—stromal tumours and the germ cell tumours. Most is known about inhibin and its related proteins in the granulosa cell—group which is not the majority of tumours, or the more aggressive group clinically. In ovarian cancer, there is an overproduction of inhibin subunits, to the degree that, in the granulosa variant of ovarian carcinoma, it can be measured in serum and is used clinically as a marker of disease (Burger et al. 1998). The role of inhibin overproduction in ovarian cancer pathogenesis remains to be clarified.

New evidence is starting to emerge with regard to the more common epithelial variants of ovarian carcinoma, but it is restricted to studies of protein expression and not the effects of the proteins on pathogenesis. Cellular localisation studies for the various proteins in epithelial tumours, including benign and malignant groups, demonstrate inconsistent staining for inhibin, with the subunit only localised in mucinous adenoma and cystic tumour with borderline malignancy (Yamashita et al. 1999). Findings in relation to protein and mRNA expression of and A subunits in various tumour subtypes has led to the conclusion that epithelial proliferation may result from an early event of unbalanced expression of inhibin and activin subunits (Zheng et al. 1998).

While the exact roles of inhibin and activin remain to be defined, there are some parallels to the role of TGFβ superfamily proteins in prostate carcinoma, where α subunit
expression changes with tumour development. However, the inconsistency between the observation that in prostate cancer the inhibin α subunit may be a tumour suppressor and is overproduced to the level that it is measurable in serum in ovarian cancer needs to be explained. In conclusion, the role of inhibins in these two endocrine-related cancers remains to be defined, but the differential expression of the α subunit in the different grades of prostate cancer and the different histological subtypes of ovarian cancer is clearly important in the process of transformation to malignancy.

Inhibin and activin have multiple known and potential roles in carcinogenesis. Their homology to TGFβ is an important factor in directing ongoing research programmes, particularly with regard to activin. It is unlikely that inhibin and activin have a dual opposing role in prostate cancer but their functions may be linked if inhibin mediates some of its actions via a dominant negative mechanism at the activin receptor. Future directions in inhibin research include genetic analysis of the mechanisms of subunit loss in high-grade disease, the search for further clues regarding its role as a tumour suppressor and the final conclusion regarding the existence of a receptor.

Activins share many similarities with TGF. They have the same mechanism of receptor recruitment and intracellular signalling utilising the Smad proteins. They share common functions in regulation of the proliferation and differentiation of cells, embryonic development, wound healing, immune function and angiogenesis. They both demonstrate the ability to inhibit cell proliferation and, importantly, when this function is disturbed the normal pattern of cell growth is not maintained, paving the way for carcinogenesis. While activin produces cellular inhibition in LNCaP prostate tumour cell lines, this response is not uniform. Further investigation of activin may show that its role is more in keeping with the escape from normal regulation by TGFβ superfamily proteins, which occurs once cancer cells are able to resist TGF-mediated growth inhibition, allowing uncontrolled proliferation. Certainly the distant effects of activin and the TGFβ isoforms involved in the establishment and progression of carcinogenesis are similar. However, activin differs from TGFβ in development, specifically due to the roles activin plays in early embryogenesis with crucial actions in mesoderm induction and dorsoventral patterning, while TGFβ is responsible for more specific changes including cardiac, lung and craniofacial and urogenital defects. Activin’s relationship with follistatin is a unique regulatory pathway, because an exact corollary for TGFβ has not been demonstrated. The interplay between TGFβ and its binding proteins occurs at a pre-activation stage and not through binding of the active ligand, such as is seen between activin and follistatin. Finally, activin has specific roles in reproduction with known changes during the menstrual cycle, pregnancy and parturition. TGFβ has not been investigated in this context.

There are overwhelming similarities that outweigh the differences between activin and TGF. What remains to be seen is the degree to which the functions of activin and TGFβ are complementary, synergistic or additive. It is also possible that their functions incorporate an element of redundancy in biological systems that would have important implications for any therapeutic interventions that were specifically targeted at one or other mediator. The continuing analysis of the function of activins in settings such as prostate cancer may answer this question.

Activin is growth inhibitory in some prostate tumour cell lines in vitro. The loss of activin’s local or autocrine growth-inhibitory capacity in high-grade disease is most probably due to its interaction with follistatin and more specifically the FS288 splice variant. Activin also mediates actions more distantly in a paracrine capacity that would favour prostate tumour growth and the extra-prostatic role for activin may be of greater significance in the development of high-grade prostate cancer. Activin is likely to be a key player in local and distant disease development. Greater knowledge of its role in cytological and physiological prostate development may further define its potential to act as a mediator, particularly in an androgen-independent state.

Once the roles for inhibins, activins and follistatins are defined in prostate development and disease, their relative expression may provide markers for prognosis and, providing they prove to have some specificity of function distinct from that of TGF, they have potential roles in therapeutic interventions.

Acknowledgements

The authors wish to thank Mr D Moss, Dr C Hovens and Dr D Phillips for assistance with the manuscript and Sally Mellor and Stephen McPherson for assistance with the manuscript and figures.

References


Barrack ER 1999 TGFβ in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 31 61–70.
Dowling and Risbridger: Inhibins and activins in prostate cancer


Lebrun JJ & Vale WW 1997 Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation. *Molecular and Cellular Biology* 17 1682–1691.


McChugge WG & Maxwell P 1999 Adenocarcinomas of various sites may exhibit immunoreactivity with anti-inhibin antibodies. *Histopathology* 35 216–220.


Robertson DM, Klein R, de Vos PL, McLachlan RI, Wettenhall RE, Heam MT, Burger HG & de Kretser DM 1987 The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin. *Biochemical and Biophysical Research Communications* 149 744–749.


Dowling and Risbridger: Inhibins and activins in prostate cancer


